240 related articles for article (PubMed ID: 19240160)
21. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
22. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
[TBL] [Abstract][Full Text] [Related]
23. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
[TBL] [Abstract][Full Text] [Related]
24. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
25. Bicalutamide enhances fodrin-mediated apoptosis through calpain in LNCaP.
Lee J; Mun S; Park A; Kim D; Heun Cha B; Kang HG
Exp Biol Med (Maywood); 2018 Jun; 243(10):843-851. PubMed ID: 29860890
[TBL] [Abstract][Full Text] [Related]
26. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
27. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Nwachukwu JC; Mita P; Ruoff R; Ha S; Wang Q; Huang SJ; Taneja SS; Brown M; Gerald WL; Garabedian MJ; Logan SK
Cancer Res; 2009 Apr; 69(7):3140-7. PubMed ID: 19318562
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
30. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
Colabufo NA; Pagliarulo V; Berardi F; Contino M; Inglese C; Niso M; Ancona P; Albo G; Pagliarulo A; Perrone R
Eur J Pharmacol; 2008 Dec; 601(1-3):38-42. PubMed ID: 18992739
[TBL] [Abstract][Full Text] [Related]
31. Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
Salman H; Bergman M; Blumberger N; Djaldetti M; Bessler H
Biomed Pharmacother; 2014 Feb; 68(1):21-4. PubMed ID: 24406295
[TBL] [Abstract][Full Text] [Related]
32. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
33. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation.
Lorenzo PI; Saatcioglu F
Neoplasia; 2008 May; 10(5):418-28. PubMed ID: 18472959
[TBL] [Abstract][Full Text] [Related]
35. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
36. Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.
Bühler P; Fischer T; Wolf P; Gierschner D; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U
Urol Int; 2010; 84(2):203-11. PubMed ID: 20215827
[TBL] [Abstract][Full Text] [Related]
37. Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Bennett HL; Stockley J; Fleming JT; Mandal R; O'Prey J; Ryan KM; Robson CN; Leung HY
BJU Int; 2013 Apr; 111(4):672-82. PubMed ID: 22897391
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
Kawabata R; Oie S; Takahashi M; Kanayama H; Oka T; Itoh K
Int J Oncol; 2011 Jun; 38(6):1489-500. PubMed ID: 21455575
[TBL] [Abstract][Full Text] [Related]
39. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
